Quarterly report · Q1

Period2022-04-01 → 2022-06-30
Filed2022-08-05
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥774.1bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥2.77T2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥639.0bn2021-04-01 → 2021-06-30Cons.Revenue IFRS
Operating income¥66.3bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥58.3bn2021-04-01 → 2021-06-30Cons.Operating profit loss IFRS
Profit before tax¥113.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥251.1bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥56.7bn2021-04-01 → 2021-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥70.0bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥162.1bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥35.7bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥85.1bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥186.4bn2021-04-01 → 2022-03-31Cons.Profit loss IFRS (5-year summary)
Net income¥38.9bn2021-04-01 → 2021-06-30Cons.Profit loss IFRS
Total assets¥4.67Tat 2022-06-30Cons.Assets IFRS
Total assets¥4.31Tat 2022-03-31Cons.Assets IFRS
Total assets¥4.09Tat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.81Tat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥2.61Tat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.86Tat 2022-06-30Cons.Equity IFRS
Net assets / equity¥1.70Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥1.50Tat 2021-06-30Cons.Equity IFRS
Net assets / equity¥1.48Tat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.34Tat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.22Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.05Tat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥498.6bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥365.4bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥366.5bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥360.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥42.6bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥171.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥4.7bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥46.0bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥115.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥41.3bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥11.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥81.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥41.5bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥42.812022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥99.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥21.812021-04-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
Equity ratio28.8%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.3%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio25.5%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥31.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥14.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥17.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥3.3bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥24.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥24.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥7.5bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-04-01 → 2022-06-30¥91.3bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-04-01 → 2022-06-30¥86.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.8bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-04-01 → 2022-06-30¥6.6bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-04-01 → 2022-06-30¥240.0bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-04-01 → 2022-06-30¥238.6bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥153.5bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥152.6bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥945m
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥21.9bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-04-01 → 2022-06-30¥114.8bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-04-01 → 2022-06-30¥114.7bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥116m
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-04-01 → 2022-06-30¥15.8bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue2022-04-01 → 2022-06-30¥167.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue external2022-04-01 → 2022-06-30¥167.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentsegment profit2022-04-01 → 2022-06-30¥14.1bn
—segment totalrevenue2022-04-01 → 2022-06-30¥767.3bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥759.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.4bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥68.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥27.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥13.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥14.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30¥2.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥21.0bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥21.0bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥5.0bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue2021-04-01 → 2021-06-30¥77.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2021-04-01 → 2021-06-30¥74.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥3.0bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2021-04-01 → 2021-06-30¥6.7bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2021-04-01 → 2021-06-30¥200.8bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2021-04-01 → 2021-06-30¥199.5bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.2bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2021-04-01 → 2021-06-30¥23.8bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2021-04-01 → 2021-06-30¥105.4bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2021-04-01 → 2021-06-30¥103.1bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.4bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2021-04-01 → 2021-06-30¥10.3bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue2021-04-01 → 2021-06-30¥109.4bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2021-04-01 → 2021-06-30¥109.3bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥110m
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2021-04-01 → 2021-06-30¥13.5bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue2021-04-01 → 2021-06-30¥139.2bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue external2021-04-01 → 2021-06-30¥139.2bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2m
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentsegment profit2021-04-01 → 2021-06-30¥9.6bn
—segment totalrevenue2021-04-01 → 2021-06-30¥632.1bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥625.4bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥6.7bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥63.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 785
ItemContextValueUnit
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-4607000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration-JPY
Other ss IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Other ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Other ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-JPY
Other ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-20000000JPY
Other ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-JPY
Other ss IFRSCurrentYTDDuration-20000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Total transactions with owners IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-4607000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-22725000000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-8403000000JPY
Total transactions with owners IFRSCurrentYTDDuration-31128000000JPY
Equity IFRSCurrentQuarterInstant_EffectivePortionOfCashFlowHedgesIFRSMember-789000000JPY
Equity IFRSCurrentQuarterInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember137984000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember208555000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember1343256000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember519979000000JPY
Equity IFRSCurrentQuarterInstant1863235000000JPY
Profit loss before tax IFRSPrior1YTDDuration56693000000JPY
Profit loss before tax IFRSCurrentYTDDuration113656000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration37569000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration43713000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration1579000000JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration-JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration-14742000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-12671000000JPY
Interest and dividend income ope cf IFRSPrior1YTDDuration-2912000000JPY
Interest and dividend income ope cf IFRSCurrentYTDDuration-4321000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration4163000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration5733000000JPY
Business structure improvement expenses ope cf IFRSPrior1YTDDuration1653000000JPY
Business structure improvement expenses ope cf IFRSCurrentYTDDuration2135000000JPY
Change in fair value of contingent consideration ope cf IFRSPrior1YTDDuration88000000JPY
Change in fair value of contingent consideration ope cf IFRSCurrentYTDDuration78000000JPY
Loss gain on sale of fixed assets ope cf IFRSPrior1YTDDuration-40000000JPY
Loss gain on sale of fixed assets ope cf IFRSCurrentYTDDuration-1896000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1YTDDuration12850000000JPY
Decrease increase in trade receivables ope cf IFRSCurrentYTDDuration28174000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-43379000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-57141000000JPY
Increase decrease in trade payables ope cf IFRSPrior1YTDDuration14700000000JPY
Increase decrease in trade payables ope cf IFRSCurrentYTDDuration62567000000JPY
Increase decrease in unearned revenue ope cf IFRSPrior1YTDDuration10626000000JPY
Increase decrease in unearned revenue ope cf IFRSCurrentYTDDuration-8119000000JPY
Increase decrease in provisions ope cf IFRSPrior1YTDDuration-2645000000JPY
Increase decrease in provisions ope cf IFRSCurrentYTDDuration9446000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass